Roche's Phase 3 Study on Polivy With Chemotherapy Regimen Met Primary Endpoint
August 09 2021 - 2:58AM
Dow Jones News
By Giulia Petroni
Roche Holding AG on Monday said that its phase 3 study on the
use of Polivy in combination with chemotherapy regimen R-CHP for
the treatment of diffuse large B-cell lymphoma met its primary
endpoint.
The Swiss pharmaceutical giant said the trial showed the use of
polatuzumab vedotin with rituximab plus cyclophosphamide,
doxorubicin and prednisone significantly improves outcomes in
patients with a previously untreated aggressive form of lymphoma
compared with standard of care.
Roche said results of the study will be submitted to health
authorities.
Write to Giulia Petroni at giulia.petroni@wsj.com
(END) Dow Jones Newswires
August 09, 2021 02:43 ET (06:43 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Apr 2023 to Apr 2024
